As of November 10, 2026, Inspire Medical Systems, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 22, 2026 to July 24, 2026, naming 1 appointment and 1 departure. The latest filing names Michael H. Carrel, appointed (Form 8-K, July 24, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Inspire Medical Systems, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Inspire Medical Systems, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-22 to 2026-07-24. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Inspire Medical Systems, Inc. files it.
Also on the record for Inspire Medical Systems, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 4.2% of the class | 5%+ stakes | Source |
| October 30, 2026 | Stake report, Schedule 13G/A, by Vanguard Portfolio Management | 6.02% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 6.7% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by AQR Capital Management, LLC | 6.44% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Vanguard Portfolio Management | 7.37% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 14.4% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13G, by D. E. Shaw & Co., L.P. | 5.1% of the class | 5%+ stakes | Source |
| May 27, 2026 | Stake report, Schedule 13G, by Soleus Capital Master Fund, L.P. | 5.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 8.8% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Deerfield Mgmt, L.P. | 4.5% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.1% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.71% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Inspire Medical Systems, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Inspire Medical Systems, Inc. and the records around it.
Inspire Medical Systems, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Marc Stad also filed stake reports on 3 other companies: Oscar Health, Inc. (Feb 2026)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), NOVOCURE LIMITED (Nov 2026)
Watch Inspire Medical Systems, Inc.
Get an email when Inspire Medical Systems, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Inspire Medical Systems, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Inspire Medical Systems, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inspire Medical Systems, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 22 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-24 | In | 8-K, 2026-07-24 | |||
| 2026-07-22 | Out | Director | 8-K, 2026-07-22 |
Who leads Inspire Medical Systems, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Casey Tansey, departure reported (filed 2026-07-22). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Inspire Medical Systems, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Inspire Medical Systems, Inc., with the record behind each one.
Find candidates like Director at Inspire Medical Systems, Inc.Every change, in the filing's words
Appointed: Michael H. Carrel
On July 20, 2026, the Board of Directors (the "Board") of Inspire Medical Systems, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Michael H. Carrel to the Board, effective immediately.
- Mr. Carrel will serve as a Class III director for a term expiring at the Company's 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal.
- In connection with the appointment of Mr. Carrel to the Board, he was also appointed to serve on the Organization and Compensation Committee and Quality, Product Supply and Technology Committee.
- Mr. Carrel, age 55, has served as President, Chief Executive Officer and director of AtriCure, Inc. (NASDAQ: ATRC), a medical device company that provides solutions, treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, since November 2012.
- His career includes successful leadership in global organizations in healthcare and technology industries.
- Before joining AtriCure, Mr. Carrel was President and Chief Executive Officer of Vital Images, Inc., a publicly-traded medical imaging software company which was acquired by Toshiba Medical Systems Corporation.
Departing: Casey Tansey, Director
On July 16, 2026, Casey Tansey, a member of the Board of Directors (the "Board") of Inspire Medical Systems, Inc. (the "Company"), notified the Company of his decision to retire from the Board (and the committees on which he serves) and not stand for re-election at the Company's 2027 Annual Meeting of Stockholders (the "2027 Annual Meeting").
- Mr. Tansey's retirement will become effective July 30, 2026.
- Mr. Tansey's decision to retire and not stand for re-election was not the result of any disagreement with the Company or any matter relating to the Company's operation, policies or practices.
Tools for this story
Each opens in a new tab, filled in for Inspire Medical Systems, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.